β-Catenin signaling in hepatocellular carcinoma

被引：152

作者：

Xu, Chuanrui ^{[1
]}

Xu, Zhong ^{[2
]}

Zhang, Yi ^{[3
]}

Evert, Matthias ^{[4
]}

Calvisi, Diego F. ^{[4
]}

Chen, Xin ^{[5
,6
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan, Peoples R China

[2] Wuhan Univ, Zhongnan Hosp, Dept Gastroenterol, Wuhan, Peoples R China

[3] Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing, Peoples R China

[4] Univ Regensburg, Inst Pathol, Regensburg, Germany

[5] UCSF, Dept Bioengn & Therapeut Sci, San Francisco, CA USA

[6] UCSF, Liver Ctr, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2022年 / 132卷 / 04期

基金：

美国国家科学基金会;

关键词：

SMALL-MOLECULE ANTAGONISTS; C-MYC EXPRESSION; CELLS IN-VITRO; CYCLIN D1 GENE; TRANSCRIPTIONAL REGULATION; DECREASED GROWTH; LIVER-CANCER; WNT; PATHWAY; INHIBITOR;

D O I：

10.1172/JCI154515

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Deregulated Wnt/beta-catenin signaling is one of the main genetic alterations in human hepatocellular carcinoma (HCC). Comprehensive genomic analyses have revealed that gain-of-function mutation of CTNNB1, which encodes beta-catenin, and loss-of-function mutation of AXIN1 occur in approximately 35% of human HCC samples. Human HCCs with activation of the Wnt/beta-catenin pathway demonstrate unique gene expression patterns and pathological features. Activated Wnt/beta-catenin synergizes with multiple signaling cascades to drive HCC formation, and it functions through its downstream effectors. Therefore, strategies targeting Wnt/beta-catenin have been pursued as possible therapeutics against HCC. Here, we review the genetic alterations and oncogenic roles of aberrant Wnt/beta-catenin signaling during hepatocarcinogenesis. In addition, we discuss the implication of this pathway in HCC diagnosis, classification, and personalized treatment.

引用

页数：11

共 157 条

[1] AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation [J].

Abitbol, Shirley ;

Dahmani, Rajae ;

Coulouarn, Cedric ;

Ragazzon, Bruno ;

Mlecnik, Bernhard ;

Senni, Nadia ;

Savall, Mathilde ;

Bossard, Pascale ;

Sohier, Pierre ;

Drouet, Valerie ;

Tournier, Emilie ;

Dumont, Florent ;

Sanson, Romain ;

Calderaro, Julien ;

Zucman-Rossi, Jessica ;

Vasseur-Cognet, Mireille ;

Just, Pierre-Alexandre ;

Terris, Benoit ;

Perret, Christine ;

Gilgenkrantz, Helene .

JOURNAL OF HEPATOLOGY, 2018, 68 (06) :1203-1213

[2] Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma [J].

Aguirre, Andrew J. ;

Hruban, Ralph H. ;

Raphael, Benjamin J. .

CANCER CELL, 2017, 32 (02) :185-+

[3] Tumor heterogeneity in small hepatocellular carcinoma:: Analysis of tumor cell proliferation, expression and mutation of p53 and β-catenin [J].

An, FQ ;

Matsuda, M ;

Fujii, H ;

Tang, RF ;

Amemiya, H ;

Dai, YM ;

Matsumoto, Y .

INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (04) :468-474

[4] The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth [J].

Arensman, Michael D. ;

Telesca, Donatello ;

Lay, Anna R. ;

Kershaw, Kathleen M. ;

Wu, Nanping ;

Donahue, Timothy R. ;

Dawson, David W. .

MOLECULAR CANCER THERAPEUTICS, 2014, 13 (10) :2303-2314

[5] Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer [J].

Arques, Oriol ;

Chicote, Irene ;

Puig, Isabel ;

Tenbaum, Stephan P. ;

Argiles, Guillem ;

Dienstmann, Rodrigo ;

Fernandez, Natalia ;

Caratu, Ginevra ;

Matito, Judit ;

Silberschmidt, Daniel ;

Rodon, Jordi ;

Landolfi, Stefania ;

Prat, Aleix ;

Espin, Eloy ;

Charco, Ramon ;

Nuciforo, Paolo ;

Vivancos, Ana ;

Shao, Wenlin ;

Tabernero, Josep ;

Palmer, Hector G. .

CLINICAL CANCER RESEARCH, 2016, 22 (03) :644-656

[6] Cholestasis is a marker for hepatocellular carcinomas displaying β-catenin mutations [J].

Audard, V. ;

Grimber, G. ;

Elie, C. ;

Radenen, B. ;

Audebourg, A. ;

Letourneur, F. ;

Soubrane, O. ;

Vacher-Lavenu, M-C ;

Perret, C. ;

Cavard, C. ;

Terris, B. .

JOURNAL OF PATHOLOGY, 2007, 212 (03) :345-352

[7] Correlation between β-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma [J].

Austinat, Madeleine ;

Dunsch, Ruediger ;

Wittekind, Christian ;

Tannapfel, Andrea ;

Gebhardt, Rolf ;

Gaunitz, Frank .

MOLECULAR CANCER, 2008, 7 (1)

[8] Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma [J].

Bengochea, A. ;

de Souza, M. M. ;

Lefrancois, L. ;

Le Roux, E. ;

Galy, O. ;

Chemin, I. ;

Kim, M. ;

Wands, J. R. ;

Trepo, C. ;

Hainaut, P. ;

Scoazec, J-Y ;

Vitvitski, L. ;

Merle, P. .

BRITISH JOURNAL OF CANCER, 2008, 99 (01) :143-150

[9] Apc tumor suppressor gene is the "zonation-keeper" of mouse liver [J].

Benhamouche, Samira ;

Decaens, Thomas ;

Godard, Cecile ;

Chambrey, Regine ;

Rickman, David S. ;

Moinard, Christophe ;

Vasseur-Cognet, Mireille ;

Kuo, Calvin J. ;

Kahn, Axel ;

Perret, Christine ;

Colnot, Sabine .

DEVELOPMENTAL CELL, 2006, 10 (06) :759-770

[10] Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines [J].

Boon, EMJ ;

Keller, JJ ;

Wormhoudt, TAM ;

Giardiello, FM ;

Offerhaus, GJA ;

van der Neut, R ;

Pals, ST .

BRITISH JOURNAL OF CANCER, 2004, 90 (01) :224-229

← 1 2 3 4 5 6 7 8 9 10 →